Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.60 |
| ▸ | METAP1 | P53582 | 2/20 | 0.52 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489926 | 0.88 | FDPS (0.63) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL5063522 | 0.86 | FDPS (0.64) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL5488043 | 0.82 | LAP3 (0.52) | FDPSMETAP1LAP3S1PR2S1PR1 | |
| SCHEMBL87849 | 0.77 | METAP1 (0.56) | FDPSMETAP1LAP3S1PR2S1PR1 | |
| SCHEMBL4095556 | 0.76 | FDPS (1.00) | FDPSMETAP1LAP3GGPS1 | |
| SCHEMBL5059527 | 0.76 | S1PR1 (0.71) | FDPSMETAP1LAP3S1PR2S1PR1 | |
| Medronic Acid SCHEMBL9684269 | 0.75 | METAP1 (0.44) | FDPSMETAP1LAP3S1PR2S1PR1 | |
| SCHEMBL5496452 | 0.75 | ANPEP (0.39) | FDPSMETAP1LAP3 | |
| Medronic Acid SCHEMBL2820764 | 0.72 | METAP1 (0.50) | FDPSMETAP1LAP3S1PR2S1PR1 | |
| SCHEMBL13326629 | 0.72 | S1PR1 (0.56) | FDPSMETAP1S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1251837-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | Neurochem, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001085093-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | NEUROCHEM, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | FDPS 1920/4885METAP1 982/4885LAP3 1400/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | FDPS 4116/4885METAP1 637/4885LAP3 1256/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FDPS 4229/4885METAP1 697/4885LAP3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.